Osteoarthritis biotech Carbylan swings for a $75M IPO

Damian Garde

Palo Alto, CA's Therapeutics has set terms for an IPO worth $ 75 million at its midpoint, working to get a treatment for pain through late-stage development.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS